Biohaven Ltd. (BHVN)
(Delayed Data from NYSE)
$14.70 USD
+1.21 (8.97%)
Updated Sep 17, 2025 04:00 PM ET
After-Market: $14.70 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth C Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BHVN 14.70 +1.21(8.97%)
Will BHVN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BHVN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BHVN
Company News for Mar 4, 2025
Company News for Jan 2, 2025
BHVN: What are Zacks experts saying now?
Zacks Private Portfolio Services
SRRK Stock Soars as Muscle Disease Drug Meets Phase III Study Goal
Biotech Stock Roundup: BHVN, WVE, ZVRA Stocks Up on Updates, BIIB & UCBs Study Data & More
BHVN Stock Up as Rare Neurological Disease Study Meets Primary Goal
Other News for BHVN
Biohaven (BHVN) Shares Surge Following Positive Analyst Coverage
Biohaven is a new Buy at Citi on potential FDA nod for lead asset
Netflix upgraded, Five Below initiated: Wall Street’s top analyst calls
Netflix upgraded, Five Below initiated: Wall Street's top analyst calls
This Protagonist Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday